Knockdown of E2F2 inhibits tumorigenicity, but preserves stemness of human embryonic stem cells

Stem Cells and Development

Volumn 23, Issue 11, 2014, Pages 1266-1274

  Suzuki, Daniela Emi ^a,b   Nakahata, Adriana Miti ^c   Okamoto, Oswaldo Keith ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BMII GENE; CANCER CELL LINE; CANCER INHIBITION; CARCINOGENICITY; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; CONTROLLED STUDY; E2F2 GENE; EMBRYO; EMBRYONIC STEM CELL; G2 PHASE CELL CYCLE CHECKPOINT; GENE; GENE EXPRESSION; GENE SILENCING; HMGA1 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTO ONCOGENE; RISK REDUCTION; TERATOMA; ANIMAL; BAGG ALBINO MOUSE; CARCINOGENESIS; CELL CULTURE; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY;

E2F2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR E2F2;

ANIMALS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; E2F2 TRANSCRIPTION FACTOR; EMBRYONIC STEM CELLS; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; TERATOMA;

EID: 84901332736     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0592     Document Type: Article

References (43)

1. Thomson JA, J Itskovitz-Eldor, SS Shapiro, MA Waknitz, JJ Swiergiel, VS Marshall and JM Jones. (1998). Embryonic stem cell lines derived from human blastocysts. Science 282:1145-1147.
2. Mintz B and K Illmensee. (1975). Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci U S A 72:3585-3589.
3. Takahashi K, K Tanabe, M Ohnuki, M Narita, T Ichisaka, K Tomoda and S Yamanaka. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-872.
4. Yu J, MA Vodyanik, K Smuga-Otto, J Antosiewicz-Bourget, JL Frane, S Tian, J Nie, GA Jonsdottir, V Ruotti, et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917-1920.
5. Lee AS, C Tang, MS Rao, IL Weissman and JC Wu. (2013). Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med 19:998-1004.
6. Riggs JW, BL Barrilleaux, N Varlakhanova, KM Bush, V Chan and PS Knoepfler. (2013). Induced pluripotency and oncogenic transformation are related processes. Stem Cells Dev 22:37-50.
7. Becker KA, PN Ghule, JA Therrien, JB Lian, JL Stein, AJ van Wijnen and GS Stein. (2006). Self-renewal of human embryonic stem cells is supported by a shortened G1 cell cycle phase. J Cell Physiol 209:883-893.
8. Edel MJ, C Menchon, S Menendez, A Raya and JCI Belmonte. (2010). Rem2 GTPase maintains survival of human embryonic stem cells as well as enhancing reprogramming by regulating p53 and cyclin D1. Genes and Development 24:561-573.
9. Edel MJ and JCI Belmonte. (2010). Cell cycle and pluripotency: Is there a direct link? Cell Cycle 9:2694-2695.
10. Kalaszczynska I, Y Geng, T Iino, S Mizuno, Y Choi, I Kondratiuk, DP Silver, DJ Wolgemuth, K Akashi and P Sicinski. (2009). Cyclin A is redundant in fibroblasts but essential in hematopoietic and embryonic stem cells. Cell 138:352-365.
11. Nakagawa M, M Koyanagi, K Tanabe, K Takahashi, T Ichisaka, T Aoi, K Okita, Y Mochiduki, N Takizawa and S Yamanaka. (2008). Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 26:101-106.
12. Menendez S, S Camus, A Herreria, I Paramonov, LB Morera, M Collado, V Pekarik, I Maceda, M Edel, et al. (2012). Increased dosage of tumor suppressors limits the tumorigenicity of iPS cells without affecting their pluripotency. Aging Cell 11:41-50.
13. McLenachan S, C Menchón, A Raya, A Consiglio and MJ Edel. (2012). Cyclin A1 is essential for setting the pluripotent state and reducing tumorigenicity of iPS cells. Stem Cells Dev 21:2891-2899.
14. Müller H, AP Bracken, R Vernell, MC Moroni, F Christians, E Grassilli, E Prosperini, E Vigo, JD Oliner and K Helin. (2001). E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev 15:267-285.
15. Johnson DG and J DeGregori. (2006). Putting the Oncogenic and Tumor Suppressive Activities of E2F into Context. Curr Mol Med 6:731-738.
16. Nowak K, K Kerl, D Fehr, C Kramps, C Gessner, K Killmer, B Samans, B Berwanger, H Christiansen and W Lutz. (2006). BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res 34:1745-1754.
17. Marie SK, OK Okamoto, M Uno, AP Hasegawa, SM Oba- Shinjo, T Cohen, AA Camargo, A Kosoy, CG Carlotti Jr, et al. (2008). Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. Int J Cancer 122:807-815.
18. Massimi I, F Guerrieri, M Petroni, V Veschi, S Truffa, I Screpanti, L Frati, M Levrero, A Gulino and G Giannini. (2013). The HMGA1 protoncogene frequently deregulated in cancer is a transcriptional target of E2F1. Mol Carcinog 52:526-534.
19. Lessard J and G Sauvageau. (2003). Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423:255-260.
20. Valk-Lingbeek ME, SW Bruggeman and M van Lohuizen. (2004). Stem cells and cancer; the polycomb connection. Cell 118:409-418.
21. Gu C, YK Banasavadi-Siddegowda, K Joshi, Y Nakamura, H Kurt, S Gupta and I Nakano. (2013). Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner. Stem Cells 31:870-881.
22. Gomez-Manzano C, P Mitlianga, J Fueyo, HY Lee, M Hu, KB Spurgers, TL Glass, D Koul, TJ Liu, TJ McDonnell and WK Yung. (2001). Transfer of E2F-1 to human gliomas cells results in transcriptional up-regulation of Bcl-2. Cancer Res 18:6693-6697.
23. Okamoto OK, SM Oba-Shinjo, L Lopes and SK Nagahashi Marie. (2007). Expression of HOXC9 and E2F2 are upregulated in CD133( + ) cells isolated from human astrocytomas and associate with transformation of human astrocytes. Biochim Biophys Acta 1769:437-442.
24. Watanabe K, M Ueno, D Kamiya, A Nishiyama, M Matsumura, T Wataya, JB Takahashi, S Nishikawa, S Nishikawa, K Muguruma and Y Sasai. (2007). A ROCK inhibitor permitssurvival of dissociated human embryonic stem cells. Nat Biotechnol 25:681-686.
25. Fernandes AM, PA Marinho, RC Sartore, BS Paulsen, RM Mariante, LR Castilho and SK Rehen. (2009). Successful scale-up of human embryonic stem cell production in a stirred microcarrier culture system. Braz J Med Biol Res 42:515-522.
26. Baharvand H, NZ Mehrjardi, M Hatami, S Kiani, M Rao and MM Haghighi. (2007). Neural differentiation from human embryonic stem cells in a defined adherent culture condition. Int J Dev Biol 51:371-378.
27. Bhagavati S and W Xu. (2005). Generation of skeletal muscle from transplanted embryonic stem cells in dystrophic mice. Biochem Biophys Res Commun 333:644-649.
28. Opavsky R, SY Tsai, M Guimond, A Arora, J Opavska, B Becknell, M Kaufmann, NA Walton, JA Stephens, et al. (2007). Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. Proc Natl Acad Sci U S A 104:15400-15405.
29. Fujiwara K, I Yuwanita, DP Hollern and ER Andrechek. (2011). Prediction and genetic demonstration of a role for activator E2Fs in Myc-induced tumors. Cancer Res 71:1924-1932.
30. Scheijen B, M Bronk, T van der Meer, D De Jong and R Bernards. (2004). High incidence of thymic epithelial tumors in E2F2 transgenic mice. J Biol Chem 279:10476-10483.
31. Chen C and AD Wells. (2007). Comparative analysis of E2F family member oncogenic activity. PLoS One 2:e912.
32. Strieder V and W Lutz. (2003). E2F proteins regulate MYCN expression in neuroblastomas. J Biol Chem 278:2983-2989.
33. Shen Q, IP Uray, Y Li, TI Krisko, TE Strecker, HT Kim and PH Brown. (2008). The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene 27:366-377.
34. Nguyen-Vu T, LL Vedin, K Liu, P Jonsson, JZ Lin, NR Candelaria, LP Candelaria, S Addanki, C Williams, et al. (2013). Liver X receptor ligands disrupt breast cancer cell proliferation through an E2F-mediated mechanism. Breast Cancer Res 15:R51.
35. Dong Q, P Meng, T Wang, W Qin, W Qin, F Wang, J Yuan, Z Chen, A Yang and Wang H. (2010). MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One 5:e10147.
36. Yeo HC, TT Beh, JJ Quek, G Koh, KK Chan and DY Lee. (2011). Integrated transcriptome and binding sites analysis implicates E2F in the regulation of self-renewal in human pluripotent stem cells. PLoS One 6:e27231.
37. Fico A, A De Chevigny, J Egea, MR Bösl, H Cremer, F Maina and R Dono. (2012). Modulating Glypican4 suppresses tumorigenicity of embryonic stem cells while preserving self-renewal and pluripotency. Stem Cells 30:1863-1874.
38. Sancho M, A Di-Gregorio, N George, S Pozzi, JM Sánchez, B Pernaute and TA Rodríguez. (2013). Competitive interactions eliminate unfit embryonic stem cells at the onset of differentiation. Dev Cell 26:19-30.
39. Heyer BS, H Kochanowski and D Solter. (1999). Expression of Melk, a new protein kinase, during early mouse development. Dev Dyn 215:344-351.
40. Nakano I, AA Paucar, R Bajpai, JD Dougherty, A Zewail, TK Kelly, KJ Kim, J Ou, M Groszer, et al. (2005). Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation. J Cell Biol 170:413-427.
41. Tarasov KV, YS Tarasova, WL Tam, DR Riordon, ST Elliott, G Kania, J Li, S Yamanaka, DG Crider, et al. (2008). B-MYB is essential for normal cell cycle progression and chromosomal stability of embryonic stem cells. PLoS One 3:e2478.
42. O'Connor MD, E Wederell, G Robertson, A Delaney, O Morozova, SS Poon, D Yap, J Fee, Y Zhao, et al. (2011). Retinoblastoma-binding proteins 4 and 9 are important for human pluripotent stem cell maintenance. Exp Hematol 39:866-879.
43. Chong JL, PL Wenzel, MT Sáenz-Robles, V Nair, A Ferrey, JP Hagan, YM Gomez, N Sharma, HZ Chen, et al. (2009). E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells. Nature 462: 930-934.